Rules for Pick of The Year (PoTY) 2023

[JohnHenry]

Happy New Year! Friends come and gather around and get your picks in. BlueWolf and I will continue our tradition to co-host the PoTY 2023.

You have until January 29, 2023 up to 11:59 PM PST to make a pick – Starting price will be January 30, 2023 closing price (per Google, unless it's shown that the Google price is incorrect). The contest will start on January 30, 2023. Any stocks trading on the NASDAQ, AMEX, NYSE or, OTC – Long or short.

We welcome IPOs if picked by the end of January 29, 2023 – Starting price will be the closing price of the IPO.

Picks submitted after January 29, 2022 are welcome – A 20% penalty of the closing price.

Short share price – Price when delisted plus a 20% penalty of the closing price.

A reverse split, split, or, symbol change – OK if you let us know prior to or on January 29, 2023. A 20% penalty for the extra research after January 29, 2023.

BlueWolf will continue to provide weekly comments and updates. Thank you BlueWolf.

Discussions and concerns are welcome. Good Luck!

[Louetta]

I'll go with NVDA long.

Thank you both for doing this.

[mrmarket]

put me down for RAVE...thanks Bluewolf and JohnHenry for running such a fun contest.

[antioch6]

I'll go with CMC. It's the top stock on my screen, and if there is any truth to those commodity supercycles, it should do very well over the next few years.

[BlueWolf]

Make sure you state whether you want to be long or short. I’ll assume long for CMC and RAVE.

[mrmarket]

always long!

[Louetta]

always long!

Gosh......

[jiesen]

Gimme an O!
Gimme an M!
Gimme an E!
Gimme an G!
Gimme an A!

What's that spell? OMGA!

That's right, I do know how to spell, and I want to go long on Omega Therapeutics this year. Here's the scoop on OMGA:

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, as well as the mechanism that controls gene expression and aspect of an organism's life. The company's platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a range without altering native nucleic acid sequences. Its modular and programmable mRNA medicines, and Omega Epigenomic Controllers are designed to target specific epigenomic loci within insulated genomic domains from genome-wide DNA-sequences with single or multiple genes to treat and cure diseases through Precision Genomic Control. The company is advancing a pipeline of development candidates covering a range of disease areas, including oncology, regenerative medicine, multigenic diseases, and select monogenic diseases. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

[jiesen]

oh, yeah, and ALWAYS LONG!

[rickflyboy]

ZIM all the way

[JohnHenry]

Nice! We have five players ready with picks. Two weeks left to get your picks in for the contest.

[JohnHenry]

Make sure you state whether you want to be long or short. I’ll assume long for CMC and RAVE.

[antioch6]

Can you change my pick to GRBK long? please!

[BlueWolf]

Can you change my pick to GRBK long? please!

Done. You now have GRBK.

[BlueWolf]

My pick this year is going to be HUBS.